Patient-Derived Induced Pluripotent Stem Cell Models for Phenotypic Screening in the Neuronal Ceroid Lipofuscinoses

Ahmed Morsy, Angelica V. Carmona, and Paul C. Trippier

Abstract: Batten disease or neuronal ceroid lipofuscinosis (NCL) is a group of rare, fatal, inherited neurodegenerative lysosomal storage disorders. Numerous genes (CLN1-CLN8, CLN10-CLN14) were identified in which mutations can lead to NCL; however, the underlying pathophysiology remains elusive. Despite this, the NCLs share some of the same features and symptoms but vary in respect to severity and onset of symptoms by age. Some common symptoms include the progressive loss of vision, mental and motor deterioration, epileptic seizures, premature death, and in the rare adult-onset, dementia. Currently, all forms of NCL are fatal, and no curative treatments are available. Induced pluripotent stem cells (iPSCs) can differentiate into any cell type of the human body. Cells reprogrammed from a patient have the advantage of acquiring disease pathogenesis along with recapitulation of disease-associated phenotypes. They serve as practical model systems to shed new light on disease mechanisms and provide a phenotypic screening platform to enable drug discovery. Herein, we provide an overview of available iPSC models for a number of different NCLs. More specifically, we highlight findings in these models that may spur target identification and drug development.

Keywords: neuronal ceroid lipofuscinosis; batten disease; induced pluripotent stem cells; screening; model systems; drug discovery

1. Introduction

Batten disease, also known as neuronal ceroid lipofuscinosis (NCL), is a group of rare pediatric neurodegenerative diseases estimated to affect 1 in 12,500 people [1]. The rarity of incidence and scarcity of disease models have limited comprehensive understanding of the pathological factors that lead to disease progression. Batten disease is classified into five primary types:

(A) Congenital NCL, where babies are born with microcephaly as the disease begins in utero [2].

(B) Infantile NCL, where symptoms such as seizures and the loss of motor function appear between the ages of 6 and 18 months with the loss of psychomotor skills, including speech. The child presents with signs of regression accompanied by the onset of epilepsy and a gradual loss of vision, hyperexcitability, restlessness, and poor sleep. After the age of 15 to 20 months, the acceleration of symptoms occurs, leading to microcephaly, truncal ataxia, dystonic features, choreoathetosis, and myoclonic jerks. By the age of 24 months, children become blind and lose all cognitive and active motor skills and usually die between the ages of 9 and 13 [3].

(C) Late infantile NCL, where symptoms such as developmental delay, ataxia, and seizures appear between the ages of 2 and 4 years old and progress rapidly to loss of motor, cognitive and language functions, ultimately becoming behaviorally abnormal and demented [3].
(D) Juvenile NCL (JNCL), the most common type of Batten disease with symptoms occurring between 5 and 10 years old and is commonly associated with the loss of vision and seizures. Further symptoms include learning difficulties, motor disturbances, including extrapyramidal and less prominent pyramidal involvement (rigidity, bradykinesia, slow steps with flexion in hips and knees, and shuffling gait), which appear around puberty and progressively lead to the loss of independent mobility. Affected children usually die during their third decade [3].

(E) Adult NCL, where symptoms are less severe and progress more slowly. The clinical picture of this type is characterized by generalized tonic seizures, myoclonus, and prominent dementia. Associated features include speech problems, cerebellar dysfunction, and parkinsonism [4,5].

The NCL disorders are genetic conditions primarily inherited in an autosomal recessive manner except in the adult form, where it is autosomal dominant. Associated genes that cause the NCL encode a number of proteins that include lysosomal luminal proteins, intracellular transmembrane proteins, plasma membrane proteins, and cytoplasmic proteins (Table 1) [6]. Because of the different gene mutations, signs and symptoms range in severity and progress at different rates. However, the main characteristics seen in all types of NCLs are nerve cell lysosomal accumulation of auto-fluorescent, electron-dense material, containing subunit c of mitochondrial ATP-synthase and/or sphingolipid activator proteins A and D. Protein mutations in NCL diseases lead to the accumulation of storage material in cells of the eye [7], brain [8], skin [9], muscle [10], and others, ultimately resulting in cell death. Accumulation leads to several mechanisms of neuronal cell death that include accelerated apoptosis and autophagic death, [11] as well as secondary destructive inflammation [12]. An established pathogenetic pathway for this group of diseases remains to be determined despite efforts to develop new biological tools that can further disease understanding and provide biomarkers to monitor disease progression and therapeutic efficacy.

Table 1. NCL Diseases and Encoded Genes/Proteins [13–15].

| Disease | GENE/Protein | Age of Onset | Known Function | Refs. |
|---------|--------------|--------------|----------------|-------|
| CLN1    | PPT1 (palmitoyl protein thioesterase 1) | 6–18 months | Palmitoy-protein thioesterase activity plays a critical role in the degradation of lipid-modified proteins via removing fatty acid residues from cysteine residues | [16] |
| CLN2    | TPP1 (tripeptidyl peptidase 1) | 2–4 years | Serine protease activity prevents intralysosomal accumulation of storage material and neuronal loss | [17,18] |
| CLN3    | CLN3, lysosomal/endosomal transmembrane protein | 4–10 years | Predicted function as a pH regulator and modulator of vesicular trafficking and fusion that promotes cellular homeostasis and neuronal survival | [19] |
| CLN4    | DNAJC5/CSPα (cysteine string protein α) | Adult | Involvement in exocytosis and endocytosis functions plays a regulatory role in ATPase activity and assists in folding proteins in synaptic vesicles | [20] |
| CLN5    | Soluble lysosomal protein | 4–7 years | Glycoside hydrolase activity modulates vesicular trafficking | [21,22] |
| CLN6    | Transmembrane protein of endoplasmic reticulum | 18 months to 6 years | Precise function remains unclear but is linked with intracellular trafficking and lysosomal function | [23] |
| CLN7    | MFSD8 (major facilitator superfamily domain-containing 8), lysosomal transmembrane protein | 2–6 years | Predicted transmembrane transporter function plays a role in preventing neuronal loss, robust accumulation of lipofuscin, reactive gliosis, and degeneration and storage accumulation in the retina | [24] |
| CLN8    | Transmembrane protein of endoplasmic reticulum | 2–7 years (Turkish variant late-infantile NCL), 5–10 (northern epilepsy) | Aids in lysosomal biogenesis through transportation from the ER to the Golgi complex and in the regulation of lipid metabolism | [25,26] |
### Table 1. Cont.

| Disease | GENE/Protein | Age of Onset | Known Function                                                                 | Refs.   |
|---------|--------------|--------------|--------------------------------------------------------------------------------|---------|
| CLN10  | CTSD (cathepsin D) | In utero     | Aspartic protease functions in an unknown neuroprotective mechanism              | [27,28] |
| CLN11  | PRGN (progranulin) | Early to mid-twenties | Known roles in inflammation, embryogenesis, cell motility and tumorigenesis | [29]    |
| CLN12  | ATP13A2      | 13–16 years  | Regulation of ion homeostasis                                                   | [30]    |
| CLN13  | CTSF (cathepsin F) | Adult       | Loss of lysosomal cysteine protease activity leads to deterioration of motor function and reduced brain function | [31]    |
| CLN14  | KCTD7 (potassium channel tetramerization domain-containing protein 7) | 8–24 months | Modulation of potassium ion channel activity                                    | [32,33] |

### 2. Approved Therapies and Ongoing Drug Discovery Efforts for the NCLs

With the limited knowledge of NCL pathology, treatment strategies, classified into enzyme therapy, gene therapy and small molecules, are focused on a variety of approaches which have resulted in two drug approvals. In 2017, the U.S. Food and Drug Administration (FDA) approved the enzyme replacement therapy, Brineura, to treat CLN2 disease. Brineura is a recombinant human TPP1 (rhTPP1) proenzyme activated in the acidic environment of the lysosome [34]. The administration of rhTPP1 is performed through catheters implanted in the lateral ventricle (intracerebroventricular) and delivered every other week [35]. Treatment with the rhTPP1 in CLN2 disease patients has shown a significant delay of motor, language and visual decline and substantial reduction in cortical volume loss [34]. In vitro, the mannose-6-phosphate post-translational modification of rhTPP1 enhanced its endocytosis, hence its function towards the restoration of TPP1 activity resulting in reduced storage material accumulation in fibroblasts [36].

Another treatment approach used for the NCLs is an adeno-associated virus (AAV)-mediated gene therapy. This treatment strategy was shown to be safe and effective in several clinical trials for lysosomal storage disorders. For more detailed information, this topic was reviewed by Sawamoto et al. in 2018 [37]. The reintroduction of the lysosomal enzyme via gene therapy has demonstrated the rescue of enzyme activity. The intracranial injections of AAV encoding human PPT1 (hPPT1) increased enzyme activity and rescued phenotypic features of Batten disease in a mouse model of CLN1 disease (Ppt1<sup>−/−</sup>) [38]. Moreover, the improvement of motor functions and learning behaviors increased with multiple injections in a dose-response manner. In a canine model of CLN2 disease, the intraventricular delivery of AAV encoding canine TPP1 (caTPP1) into the circulating CSF led to widespread transduction of AAV-caTPP1 to the ependymal lining of the third and fourth ventricles and the secretion and increase of the levels of caTPP1 in the cortex and cerebellum [39]. This increase has led to delayed onset of Batten disease symptoms, reduced glial activation, rescued behavioral phenotypes, and increased longevity [39]. In another study, driving the expression of AAV9–hCLN3 vector by one of two promoters, a Mecp2 promoter or a chicken β-actin (CB) promoter, resulted in three-fold to eight-fold increase in CLN3 expression when delivered intravenously into CLN3<sup>Δex7/8</sup> mice. Moreover, this resulted in correcting multiple disease pathologies, including motor coordination, reduced astrocytes, microglial activation, and lysosomal pathology [40,41]. In a phase I/IIa clinical trial (NCT03770572), the use of an AAV9 capsid carrying the AAV2 gene cassette with hCLN3 injected intrathecally into the subarachnoid space of the lumbar spine of patients reported widespread CNS expression and a reduction in pathological hallmarks. Similarly, the administration of ovine CLN5 encoded in AAV9 vectors in a sheep model of CLN5 disease showed a substantial delay in brain atrophy and visual decline [42]. These data supported the benefits of CLN5 gene therapy, and the FDA has granted orphan drug
approval to Neurogene’s gene therapy towards CLN5 disease [43]. In a CLN6\textsuperscript{ncf} mouse model, a single intracerebroventricular injection of scAAV9.CB.hCLN6 and intrathecal injection in non-human primates resulted in the increased expression of CLN6 in the CNS, including in the eye and optic nerve. The increase of CLN6 led to a significant reduction in lysosomal storage materials and enhanced autophagy [19].

Small molecule therapies that improve lysosomal or autophagic function and others that serve as immune modulators or neuroprotective agents have been extensively investigated (Figure 1) [44,45]. Lysosomotropic agents that include cysteamine, phosphocysteamine, cysteamine bitartrate (Cystagon) and N-acetylcysteine block ceroid accumulation by being transported to lysosomes and inhibiting the formation of cysteine thioesters [46,47]. Phosphocysteamine (Figure 1) reduced ceroid accumulation and storage materials in a CLN1 disease mouse model and CLN1 diseased patients [46,48,49]. Further, a pilot clinical trial (NCT00028262) using the combination of cysteamine bitartrate (Cystagon\textsuperscript{®}) and N-acetylcysteine (Figure 1) resulted in a modest improvement in patients carrying severe CLN1 disease mutations [50]. Another class of therapeutics tested in a mouse model of JNCL are phosphodiesterase-4 (PDE4) inhibitors (such as rolipram, roflumilast, and PF-06266047) which showed an increase in cyclic adenosine monophosphate (cAMP) levels in CLN3\textsuperscript{Δex7/8} mice treated with PDE4 inhibitors showed increased brain cAMP levels and reduced neuronal apoptosis and neuroinflammation, and increased glutamate transporter expression [51]. Moreover, significant improvements in motor functions, decreased neuroinflammation, glial activation, and lysosomal pathology were observed compared to wild-type animals [51]. The immunomodulatory agents, fingolimod and teriflunomide (Figure 1), showed improved motor skills and reduced CLN3 disease severity when tested in a CLN3 disease mouse model [52]. Similarly, immunosuppressive agents such as mycophenolate mofetil demonstrated similar results when tested in a CLN3 disease mouse model [53]. In a double-blind placebo-controlled phase II trial (NCT01399047), mycophenolate mofetil was shown as well-tolerated in controlling secondary autoimmunity and neuroinflammation. However, it did not demonstrate definite effects to confer a clinical benefit [54].

Trehalose, a disaccharide composed of two glucose molecules, and MK2206, an anticancer agent, act by activating transcription-factor EB (TFEB) by inhibiting the serine/threonine kinase Akt, independently of the mechanistic target of rapamycin complex 1 (mTORC1), a known TFEB inhibitor [55–57]. This mechanism was shown to reduce lipofuscin buildup in CLN3 fibroblasts and mouse models [58]. One disadvantage of the translation of trehalose to the clinic is that the enzyme trehalase inactivates the small molecule through lysis in the small intestine. Pre-clinical evaluation of the intravenous delivery of trehalose, combined with miglustat, a trehalase inhibitor, is currently ongoing [59]. Other drugs with anti-apoptotic action in the NCLs, including flupirtine and retigabine, have shown promising results in inhibiting apoptosis, decreasing ceramide levels, and preserving cell survival in CLN1, CLN2, CLN3, CLN6, and CLN8 cultured patient lymphoblasts and neurons [44,60,61].

The study of flupirtine derivatives that enhance autophagy and induce the anti-apoptotic protein Bcl-2 in “neuron-like” PC12 cells and healthy iPSC-derived neurons has identified more potent analogs [62]. These potent compounds have resulted in the clearance of subunit c accumulation by mTOR-independent modulation of autophagy, conferred protective effects through the induction of Bcl-2, and rescued mitochondrial dysfunction in an iPSC-derived CLN3 neuron model [63]. Interestingly, in a CLN3 disease mouse model, results showed that different proteins were being impacted based on gender. Female mice treated with flupirtine showed a significant increase in Bcl-xl, an anti-apoptotic protein. Despite different proteins being affected in male versus female mice, this ultimately led to the upregulation of anti-apoptotic pathways and caused decreased cell death in the brains of flupirtine treated CLN3 mouse models [64].
The use of animal models to study the NCLs has expanded in the last decade [65–68]. Animals that have naturally occurring neurological deficits relevant to the NCLs or are genetically engineered to mimic specific NCL genes were used as screening tools for evaluating potential therapies for human NCLs. These animals include large animals, such as dogs, pigs and sheep, or small rodents such as mice and rats, or non-mammalian models that include zebrafish, yeast, and fruit fly. Although each of these models have limitations and lack reliability regarding their translation to the clinic, they serve as tools to improve the understanding of the pathology of NCL disease progression, improve the accuracy of models of the NCLs and allow elucidation of therapeutic delivery mechanisms, pharmacodynamics, and toxicology. Genetically creating a homozygous deletion of either the entire exon 4 (Ppt1Δex4) or exon 9 (Ppt1Δex9) of the PPT1 genome has replicated CLN1 disease phenotypic features, which includes the accumulation of autofluorescent granular osmiophilic deposits and prominent loss of GABAergic interneurons in several brain areas [69]. Pre-clinical evaluation of enzyme replacement and gene therapies were first performed in TPP1 deficient mice (Tpp1−/−), a model of CLN2 disease [70,71]. For CLN3 disease, several large gene deletion methods (CLN3−/−, CLN3Δex1−6, CLN3Δex7−8) have led to models that mimic the human mutation and convey similar disease progression that includes early glial activation followed by neuronal loss [72]. Anti-inflammatory and candidate gene therapy studies have used these mouse models for pre-clinical development [41,73,74]. Established animal models for studying retinal degeneration in CLN3 disease are lacking. Wiley and colleagues investigated the use of AAV-based gene augmentation to treat degenerative retinal blindness caused by CLN3 disease mutations. First, induced pluripotent stem cells (iPSCs) were generated from two patients harboring CLN3 mutations. A clinical-grade AAV2 carrying the full-length human CLN3 gene was developed and delivered to patient-specific fibroblasts and iPSC-derived retinal neuronal cells in which it was able to restore the full-length CLN3 transcript and protein successfully. In follow-up in vivo toxicity studies in wild-type mice, the purified AAV2-CLN3 showed no retinal toxicity [74]. This study provides meaningful insights and can potentially be the first step towards testing AAV-based gene augmentation clinical trials in children with
CLN3 disease. To this end, mouse models are a vital part of NCL disease research; however, they face challenges for translation into the clinic, which include neurodevelopmental, neuroanatomical, and mechanistic differences between mice and humans and apparent phenotypic presentation of NCL models [75,76]. These differences hindered the success of several clinical trials wherein therapies with promising effects in mouse models lacked efficacy in patients [50,77].

4. NCL Cellular Models

Despite extensive research to understand the molecular cell biology of processes that lead to the neurodegeneration seen across the NCLs, the lack of phenotypic in vitro model systems for drug screening hinders clinical development. This leads to highly challenging drug discovery campaigns and limits the information about natural disease history and its incompletely characterized pathophysiology. The recently reviewed cellular models of Batten disease by Minnis et al. carry many advantages in elucidating complex biological systems [78]. However, they carry fundamental limitations that hinder their use as drug screening models. Yeast models offer a unique experimental model system to examine protein functions or cellular pathways that mediate the secretion, aggregation, and subsequent toxicity of proteins associated with mutations in CLN genes [79]. However, yeast is primitive when compared to neurons, and their natural unicellular classification lacks morphological structures such as dendrites, axons, synapses, and associated specialized functions [80]. Dictyostelium discoideum is an amoeba proven to be an excellent model organism to research neurodegenerative diseases, including the NCLs [81]. However, the model has several disadvantages including that glycosylation pattern may differ from human native protein, preferential codon usage, and cultivation processes have yet to be optimized for industrial scale production [82]. Mouse cellular models are also used in studying the NCLs [65] but carry the known disadvantage that mouse brain cells have distinct biological functions compared to those of humans. It can also be argued that predictions of drug efficacy in human neurodegenerative diseases using mouse models are mostly unsuccessful [83,84]. Human primary fibroblasts and lymphoblasts are widely utilized and were historically included for biochemical confirmation of disease. However, using these models can be unreliable as the pathology of Batten disease is incomplete in the skin or blood [85,86]. Exploring new technologies to generate in vitro models from patient-derived iPSCs has gained increasing traction, especially in neurodegenerative diseases [87–90].

5. iPSC-Based Phenotypic Modeling for Drug Discovery in The NCLs

Recent advances in the ability to reprogram patient iPSCs have provided a novel means to generate phenotypic disease-relevant cells for in vitro disease modeling [91,92]. Technology introduced by Yamanaka and colleagues using the transcription factors OCT4, SOX2, KLF4, and c-MYC in somatic cells to generate human iPSCs established a reliable method to produce stem cells [92,93]. Practically, human iPSCs can differentiate into any cell type of the human body; thus, patient iPSCs can provide a source of cells that foster a precise pattern of genetic variants with the advantage of acquiring the pathogenesis of the disease and recapitulating phenotypes of various human neurodegenerative diseases in an appropriate microenvironment. Consequently, iPSCs have become well-established models for some human diseases [94–96]. In addition, advancements in techniques used in iPSC culture and the development of robust patient cell maturation and differentiation protocols have enabled plausible methods for phenotypic drug screening in iPSC-derived disease-target cells [93,97,98]. However, several technical aspects should be considered when applying this approach. For instance, variability in the phenotypes of iPSC lines derived from individual patients can result in misleading pathological mechanisms or drug effects. Therefore, current gene-editing technology, such as clustered regularly interspaced short palindromic repeats (CRISPR), has allowed researchers to regulate genetic background by generating isogenic control lines for a specific patient sample and a set of genetically defined human iPSC lines for disease modeling [99,100]. For example, Zhang et al.
generated a human iPSC line (LEIi004-A) from a patient diagnosed with late-onset non-syndromic CLN3-associated retinitis pigmentosa [101]. Primary dermal fibroblasts were reprogrammed using non-viral and non-integrating episomal plasmids expressing OCT4, SOX2, KLF4, L-MYC, LIN28, p53 short hairpin RNA, and mir302/367 microRNA. Additionally, the same group created an isogenic control line (LEIi004-A-1) using CRISPR/Cas9 gene editing to correct a CLN3 mutation. Burnight et al. also used CRISPR/Cas9 gene editing to successfully correct genomic DNA and restore the CLN3 transcript in two independent patient iPSC lines [102]. Their studies revealed that correction of the genomic deletion was substantially more difficult in the patient-derived iPSCs obtained from a heterozygote individual compared to an individual being homozygous for the common 1.02 kb deletion. In another model of CLN3 disease, CRISPR/Cas9 gene-editing technology was also used to introduce a disease-causing mutation into healthy human iPSCs in a cerebral organoid model [103]. The model was used to study early brain development; results obtained from this study revealed that a mutation in CLN3 severely affected brain development as some of the CLN3 mutant organoids were unable to develop normally while the rest demonstrated transcriptional and metabolomic changes, which in turn affected development, corticogenesis, and synapses. Decreased cerebral tissue metabolites such as creatinine and gamma-aminobutyric acid (GABA) were also observed. These results suggest that a mutation in CLN3 disease can cause neurodevelopmental changes. Overall, these gene-corrected, patient-derived iPSCs provide essential insights towards the treatment of Batten disease. Another hurdle for modeling disease with iPSC-derived cells is that the maturity of derived neurons and differentiation time required for phenotypes to emerge may vary across iPSC lines [104].

Given the great potential for the use of iPSC technology in developing a phenotypic model for human disease [99,100], we provide an overview of iPSC technology in modeling NCL diseases in the following section, including essential findings in drug development and newly established iPSC models that can be used for drug screening in NCL diseases (Table 2).

Table 2. Currently available NCL iPSC lines.

| Name | NCL | Controls | Treatment | Summary | Refs. |
|------|-----|----------|-----------|---------|-------|
| New York Stem Cell Foundation (Multiple) | CLN3 | Parent cells available | - | - | [101] |
| Cedars Sinai iPSC Core (Multiple) | CLN6 | Parent cells available | - | - | [101] |
| LEIi004-A | CLN3 | Isogenic (LEIi004-A-1) | - | - | [101] |
| Sima et al. | CLN1 & CLN2 | WT control | δ-Tocopherol (DT) and hydroxyspropyl-β-cyclodextrin (HPβCD) | Treatment reduced lipid accumulation and lysosomal enlargement | [105] |
| Lojewski et al. | CLN2 & CLN3 | WT control | Fenofibrate, gemfibrozil and PTC124 | Fenofibrate and gemfibrozil failed to increase TPP1 activity. While PTC124 resulted in an increase of TPP1 activity and attenuation of neuropathology in patient iPSC-derived neural progenitor cells | [106] |
| Wiley et al. | CLN3 | IMR90 control | Adeno-associated adenovirus serotype 2 (AAV2) carrying human CLN3 | AAV2-CLN3 restored CLN3 patient-specific transcript and protein in fibroblasts and iPSC-derived retinal neurons | [74] |
| Kinarivala et al. | CLN3 | IMR90 control | Flupirtine derivatives | Neuroprotective molecules upregulated Bcl-2, modulated autophagy, enhanced clearance of subunit c and rescued mitochondrial dysfunction | [63] |
| Tang et al. | CLN3 | WT control | CLN3 gene supplementation | Gene therapy rescued phagocytosis of photoreceptor outer segment in CLN3 disease iPSC-RPE cells | [107] |
| Uusi-Rauva et al. | CLN5 | WT control | - | Phenotypic characterization of CLN5 patient-derived iPSCs showed accumulation of autofluorescent storage material and subunit c of the mitochondrial ATP synthase | [108] |
Sima et al. differentiated neural stem cells (NSCs) from three patient dermal fibroblast lines (purchased from the Coriell Cell Repository): one from a CLN1 patient carrying a mutation in PPT1 gene that encodes the enzyme PPT1, and two from CLN2 patients carrying mutations in the TPP1 gene that encodes the enzyme tripeptidyl peptidase 1. The deficiency in lysosomal enzymes PPT1 in CLN1 disease or TPP1 in CLN2 disease results in lysosomal accumulation of lipids and subsequently the enlargement of lysosomes in patient cells, lipid droplet accumulation, and lysosomal storage of subunit c [105]. The differentiation of iPSCs derived from those patients to NSCs has afforded a valid disease model that can be used in the phenotypic screening of drugs that ameliorate disease state. For instance, enzyme replacement therapy rescued lipid accumulation and lysosomal enlargement in the diseased fibroblast cells. This study identified that δ-tocopherol (DT) was able to rescue the NCL phenotypes of enlarged lysosomes with a reduction in lipid droplet accumulation and lysosomal storage of subunit c by approximately 40% [105].

Lojewski et al. generated iPSCs from two CLN2 and four CLN3 disease patients with mutations in TPP1 and CLN3, respectively [106]. The developed iPSCs possessed abnormal lysosomal and autophagic compartments. The differentiation of CLN3 patient-derived iPSCs to neural progenitor cells (NPCs) showed distinct Golgi and endosomal/lysosomal marker staining patterns compared to control and exhibited NCL-like storage and organelle abnormalities. To validate this model as a screening model, the overexpression of non-mutated TPP1 or CLN3 was able to rescue subunit c accumulation in lysosomes in the patient-derived NPCs [106]. These findings validated AAV-mediated gene therapy, currently in clinical trial (NCT01414985).

In a follow-up study, the derivation of iPSCs from CLN3 disease patients and subsequent differentiation to NPCs were used as a phenotypic model to validate the effect of a small molecule autophagy modifier, identified from a screen conducted in a homozygous CbClN3\textsuperscript{Δex7/8} cell line stably expressing GFP-LC3 transgene [109]. This model demonstrated the accumulation of the autophagy protein LC3 by constitutively expressing a GFP-LC3 fusion. A novel biochemical assay was developed as a screening tool to validate drug efficacy. Thapsigargin, an ER Ca\textsuperscript{2+} ATPase inhibitor, was found to increase GFP-LC3 puncta in CLN3\textsuperscript{Ivs13/E15} and CLN3\textsuperscript{hom Δex7/8} iPSC-derived NPCs. The study linked CLN3 disease mutation to abnormal maintenance of intracellular Ca\textsuperscript{2+} storage, supporting findings that Ca\textsuperscript{2+} and other ions induce homeostatic disturbances present in other forms of NCL [110].

In another engineered model for drug screening of CLN3 disease, Kinarivala et al. demonstrated the characterization of a dysfunctional CLN3 patient iPSC-blood-brain barrier (BBB) and detailed a CLN3 diseased patient iPSC-derived neuron model that recapitulates multiple phenotypes of the disease [63]. This study was the first to report an iPSC-derived model of the BBB for CLN3 disease. Brain microvascular endothelial cells (BMECs) differentiated from CLN3 patient-derived iPSCs showed an impaired barrier phenotype, a compromised barrier function, and an angiogenic phenotype compared to the control. The developed neural model demonstrated the inclusion of lipofuscin within lysosomes and the accumulation of subunit c of ATP synthase, which implicated dysfunctional autophagy. Furthermore, the iPSC model showed mitochondrial impairment, the alteration of lysosomal pH and accelerated apoptosis of neurons, recapitulating key phenotypes of CLN3 disease. This phenotypic model may be suitable for screening drugs that act as autophagy modulators, anti-apoptotic compounds, and compounds with effects on mitochondria, or a combination. The model was used to screen constituent compounds of an in-house library which resulted in upregulated expression of Bcl-2, suppressed ceramide levels and activation of autophagy, directly countering three phenotypes of CLN3 disease. Furthermore, subunit c of mitochondrial ATP synthase accumulation was significantly reduced upon treatment with selected compounds. This model was the first reported to employ CLN3 patient iPSC-derived neurons for small molecule screening and reasoned that developing a phenotypic assay around autophagy in an accurate genetic model could serve as a useful starting point in fulfilling the promise of iPSC technology to discover new therapeutics for the NCLs.
More recently, a study aimed to understand the role of CLN3 in retinal pigment epithelium (RPE) structure and function by generating iPSC-RPE cells from fibroblasts of CLN3 disease patients has implicated the contribution of the CLN3 gene in RPE dysfunction and photoreceptor outer segment (POS) phagocytosis in CLN3 disease [107]. The CLN3 iPSC-RPE cells showed an affected structure and function in a cell autonomous manner when compared to control; moreover, the RPE structure necessary for POS phagocytosis was also abnormal and decreased apical RPE microvilli density, and reduced POS binding was also observed which resulted in the lower uptake of POS by CLN3 iPSC-RPE cells. Consistent with the impaired lysosomal degradation of POS by RPE cells in CLN3 disease pathology [111], CLN3 in iPSC-RPE cells was colocalized with the lysosomal marker LAMP1. This study, therefore, suggested that RPE cells may be a crucial gene therapy target to combat the loss of vision phenotype in CLN3 disease [107].

Another study focused on developing a CLN5 disease model that demonstrates phenotypic characteristics has employed CLN5 patient-derived iPSCs. Upon differentiation into neurons, these cells exhibit the accumulation of autofluorescent storage material and subunit c of mitochondrial ATP synthase. Further, morphological changes in the intracellular organelles of both the lysosomal compartment and the ER were detected. These findings reiterate previous findings of disturbances in lysosomal structures and ER stress in CLN5-deficient cells. Most of the disease mutations lead to the retention of the protein to the lysosome and ER [108].

While only a limited number of NCL iPSCs are currently described in the literature, efforts continue apace to provide more models for the research community. The New York Stem Cell Foundation (NYSCF) has partnered with the Beyond Batten Disease Foundation (BBDF) to create a collection of CLN3 iPSCs from 24 individual patients and family members to be made commercially available. Similarly, the iPSC core at Cedars Sinai has recently made available to the research community a number of CLN6 iPSC lines.

6. Conclusions

The NCLs encompasses a group of rare, fatal, pediatric neurodegenerative lysosomal storage disorders. Several gene mutations (CLN1–CLN8, CLN10–CLN14) can lead to NCL; however, a partial understanding of the function of the disease-associated proteins has hindered therapy development. Current treatment options are only symptomatic and focus on delaying progression. To date, there are only two clinically approved drugs, Brineuria, for the treatment of CLN2 disease, and Neurogene’s recently approved gene therapy to treat CLN5 disease. Different organism models have become available for NCL disease research which have provided a myriad of important information about the protein function or dysfunction for each of the associated genes, possible disease mechanisms, and have enabled detailed preclinical studies and in a small number of cases, clinical trials.

Herein, we have highlighted the contributions of different disease models to NCL research, focusing on the established patient-derived iPSC phenotypic screening models. The ability of iPSCs to encompass the precise pattern of genetic variants, along with acquiring disease pathogenesis and phenotype makes them a more translational model compared to mice and eliminates the problem of species difference. However, compared to animal models, fewer iPSC models currently exist.

The brain is a complex network of many different cellular phenotypes and screening compounds in just one phenotype, i.e., neurons, is not a complete representation of the environment in the brain. While most studies in NCL patient-derived iPSCs employ either NPCs or neurons there are emerging studies looking at biochemical and pathophysiology effects of NCL on other cell phenotypes, one such example is the use of BMECs to model the blood-brain barrier that identified an impaired barrier phenotype in CLN3. Differentiation of iPSCs into other phenotypes including oligodendrocytes, astrocytes, microglia etc. is ongoing and results are expected in due course. These cell types will allow the construction of increasingly complex co-culture models that more readily represent the human brain and thus allow a greater understanding of the disease. However, for drug screening processes,
these co-culture systems are complex, expensive, and unsuitable for high throughput. Thus, at the present time, phenotypic screening of compound libraries will likely continue to focus on one cellular type with NPCs representing an excellent phenotypic model combined with relatively low cost and rapid growth and characterization. Once promising compounds are identified, further studies in other cell types will be warranted to fully characterize the effects of a lead compound.

Despite this scarcity of NCL patient iPSCs available to the research community, the past years saw reports of the first iPSC-based screenings to identify new hit and lead compounds for NCL drug discovery. The increasing commercial availability of CLN3 patient-derived iPSC cell lines opens this highly phenotypic resource up to the non-specialized researcher. Thus, the drug discovery specialist has a new tool to enhance translational therapeutic discovery for the NCLs, through which the identification and development of novel therapeutic options to help improve lifespan and quality of life for children suffering from this deadly disease may be facilitated.

Author Contributions: A.M. and A.V.C.; wrote and proofread the manuscript. P.C.T.; devised the research, proofread the manuscript and provided critical feedback. All authors have read and agreed to the published version of the manuscript.

Funding: We thank the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under Award R01HD106590 and the University of Nebraska Medical Center for funding support. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflicts of Interest: P.C.T. is a named inventor on a patent application describing compounds for the treatment of Batten Disease, United States Patent Application US20210023064A1.

References

1. Santavuori, P.; Lauronen, L.; Kirveskari, K.; Aberg, L.; Sainio, K.; Autti, T. Neuronal ceroid lipofuscinoses in childhood. Neurology 2004, 62, S35–S41. [CrossRef] 2. Siintola, E.; Partanen, S.; Stromme, P.; Haapanen, A.; Haltia, M.; Mole, S.E. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum. Mutat. 2012, 33, 42–63. [CrossRef] [PubMed] 3. Marques, A.R.A.; di Spiezio, A.; Thiessen, N.; Schmidt, L.; Grotzinger, J.; Lullmann-Rauch, R.; Damme, M.; Storck, S.E.; Pietrzik, C.U.; Fogh, J.; et al. Enzyme replacement therapy with recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis. Autophagy 2020, 16, 811–825. [CrossRef] [PubMed] 4. Prasad, A.; Kaye, E.M.; Alroy, J. Electron microscopic examination of skin biopsy as a cost-effective tool in the diagnosis of lysosomal storage diseases. J. Child Neurol. 2018, 33, 2341–2358. [CrossRef] [PubMed] 5. Umehara, F.; Higuchi, I.; Tanaka, K.; Niiyama, T.; Ezaki, J.; Kominami, E.; Osame, M. Accumulation of mitochondrial ATP synthase subunit c in muscle in a patient with neuronal ceroid lipofuscinosis (late infantile form). Acta Neuropathol. 1999, 93, 628–632. [CrossRef] [PubMed] 6. Kousi, M.; Lehesjoki, A.E.; Mole, S.E. Progress in neuropathology of the neuronal ceroid lipofuscinoses. Mol. Genet. Metab. 1999, 66, 367–372. [CrossRef] 7. Goebel, H.H.; Schochet, S.S.; Jaynes, M.; Bruck, W.; Kohlschutter, A.; Henlatti, F. Progress in neuropathology of the neuronal ceroid lipofuscinoses. Mol. Genet. Metab. 2006, 93, 129–167. [CrossRef] [PubMed] 8. Williams, R.E.; Mole, S.E. New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology 2012, 79, 183–191. [CrossRef]
14. Mukherjee, A.B.; Appu, A.P.; Sadhukhan, T.; Casey, S.; Mondal, A.; Zhang, Z.; Bagh, M.B. Emerging new roles of the lysosome and neuronal ceroid lipofuscinoses. Mol. Neurodegener. 2019, 14, 4. [CrossRef]

15. Carcel-Trullols, J.; Kovacs, A.D.; Pearce, D.A. Cell biology of the NCL proteins: What they do and don’t do. Biochim. Biophys. Acta. 2015, 1852, 2242–2255. [CrossRef]

16. Bellizzi, J.J., 3rd; Widom, J.; Kemp, C.; Lu, J.Y.; Das, A.K.; Hofmann, S.L.; Clardy, J. The crystal structure of palmitoyl protein thioesterase 1 and the molecular basis of infantile neuronal ceroid lipofuscinosis. Proc. Natl. Acad. Sci. USA 2000, 97, 4573–4578. [CrossRef] [PubMed]

17. Kohlschutter, A.; Schulz, A.; Bartsch, U.; Storch, S. Current and emerging treatment strategies for neuronal ceroid lipofuscinoses. CNS Drugs 2019, 33, 315–325. [CrossRef]

18. Fietz, M.; AlSayed, M.; Burke, D.; Cohen-Pfeffer, J.; Cooper, J.D.; Dvorakova, L.; Giugliani, R.; Izzo, E.; Jahnova, H.; Lukacs, Z.; et al. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis. Mol. Genet. Metab. 2016, 119, 160–167. [CrossRef] [PubMed]

19. Johnson, T.B.; Cain, J.T.; White, K.A.; Ramirez-Montealegre, D.; Pearce, D.A.; Weiner, J.M. Therapeutic landscape for batten disease: Current treatments and future prospects. Nat. Rev. Neuro. 2019, 15, 161–178. [CrossRef]

20. Yap, S.Q.; Mathavarajah, S.; Huber, R.J. The converging roles of Batten disease proteins in neurodegeneration and cancer. iScience 2021, 24, 102337. [CrossRef] [PubMed]

21. Mamo, A.; Jules, F.; Dumaresq-Doiron, K.; Costantino, S.; Lefrancois, S. The role of ceroid lipofuscinosis neuronal protein 5 (CLN5) in endosomal sorting. Mol. Cell. Biol. 2012, 32, 1855–1866. [CrossRef]

22. Huber, R.J.; Mathavarajah, S. Cln5 is secreted and functions as a glycoside hydrolase in Dictyostelium. Cell. Signal. 2018, 42, 236–248. [CrossRef]

23. Sun, G.; Yao, F.; Tian, Z.; Ma, T.; Yang, Z. A first CLN6 variant case of late infantile neuronal ceroid lipofuscinosis caused by a homozygous mutation in KCTD7 links neuronal ceroid lipofuscinosis to the ubiquitin-proteasome system. Am. J. Hum. Genet. 2018, 91, 15281–15287. [CrossRef]

24. McBride, J.L.; Neuringer, M.; Ferguson, B.; Kohama, S.G.; Tagge, I.J.; Zweig, R.C.; Renner, L.M.; McGill, T.J.; Stoddard, J.; Peterson, S.; et al. Discovery of a CLN7 model of Batten disease in non-human primates. Neurobiol. Dis. 2018, 119, 65–78. [CrossRef] [PubMed]

25. Luzio, J.P. CLN8 safeguards lysosome biogenesis. Nat. Cell Biol. 2018, 20, 1333–1335. [CrossRef] [PubMed]

26. di Ronza, A.; Bajaj, L.; Sharma, J.; Sanagasetti, D.; Lotfi, P.; Adamski, C.J.; Collette, J.; Palmieri, M.; Amawi, A.; Popp, L.; et al. CLN8 is an endoplasmic reticulum cargo receptor that regulates lysosome biogenesis. Nat. Cell Biol. 2018, 20, 1370–1377. [CrossRef] [PubMed]

27. Hersheson, J.; Burke, D.; Clayton, R.; Anderson, G.; Jacques, T.S.; Mills, P.; Wood, N.W.; Gissen, P.; Clayton, P.; Fearnley, J.; et al. Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology. Neurology 2014, 83, 1873–1875. [CrossRef]

28. Hersheson, J.; Burke, D.; Clayton, R.; Anderson, G.; Jacques, T.S.; Mills, P.; Wood, N.W.; Gissen, P.; Clayton, P.; Fearnley, J.; et al. Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology. Neurology 2014, 83, 1873–1875. [CrossRef]

29. Hersheson, J.; Burke, D.; Clayton, R.; Anderson, G.; Jacques, T.S.; Mills, P.; Wood, N.W.; Gissen, P.; Clayton, P.; Fearnley, J.; et al. Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology. Neurology 2014, 83, 1873–1875. [CrossRef]

30. Hersheson, J.; Burke, D.; Clayton, R.; Anderson, G.; Jacques, T.S.; Mills, P.; Wood, N.W.; Gissen, P.; Clayton, P.; Fearnley, J.; et al. Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology. Neurology 2014, 83, 1873–1875. [CrossRef]

31. Hersheson, J.; Burke, D.; Clayton, R.; Anderson, G.; Jacques, T.S.; Mills, P.; Wood, N.W.; Gissen, P.; Clayton, P.; Fearnley, J.; et al. Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology. Neurology 2014, 83, 1873–1875. [CrossRef]

32. Hersheson, J.; Burke, D.; Clayton, R.; Anderson, G.; Jacques, T.S.; Mills, P.; Wood, N.W.; Gissen, P.; Clayton, P.; Fearnley, J.; et al. Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology. Neurology 2014, 83, 1873–1875. [CrossRef]

33. Hersheson, J.; Burke, D.; Clayton, R.; Anderson, G.; Jacques, T.S.; Mills, P.; Wood, N.W.; Gissen, P.; Clayton, P.; Fearnley, J.; et al. Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology. Neurology 2014, 83, 1873–1875. [CrossRef]

34. Hersheson, J.; Burke, D.; Clayton, R.; Anderson, G.; Jacques, T.S.; Mills, P.; Wood, N.W.; Gissen, P.; Clayton, P.; Fearnley, J.; et al. Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology. Neurology 2014, 83, 1873–1875. [CrossRef]

35. Hersheson, J.; Burke, D.; Clayton, R.; Anderson, G.; Jacques, T.S.; Mills, P.; Wood, N.W.; Gissen, P.; Clayton, P.; Fearnley, J.; et al. Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology. Neurology 2014, 83, 1873–1875. [CrossRef]

36. Hersheson, J.; Burke, D.; Clayton, R.; Anderson, G.; Jacques, T.S.; Mills, P.; Wood, N.W.; Gissen, P.; Clayton, P.; Fearnley, J.; et al. Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology. Neurology 2014, 83, 1873–1875. [CrossRef] [PubMed]
39. Katz, M.L.; Tecedor, L.; Chen, Y.; Williamson, B.G.; Lysenko, E.; Wininger, F.A.; Young, W.M.; Johnson, G.C.; Whiting, R.E.; Coates, J.R.; et al. AAV gene transfer delays disease onset in a TP1P1-deficient canine model of the late infantile form of Batten disease. Sci. Transl. Med. 2015, 7, 313ra180. [CrossRef] [PubMed]

40. Cotman, S.L.; Vrabac, V.; Lebel, L.A.; Lee, R.L.; Johnson, K.A.; Donahue, L.R.; Teed, A.M.; Antonellis, K.; Bronson, R.T.; Lerner, T.J.; et al. Cln3(Δex7/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth. Hum. Mol. Genet. 2002, 11, 2709–2721. [CrossRef]

41. Bosch, M.E.; Aldrich, A.; Fallet, R.; Odvody, J.; Burkovetskaya, M.; Schuberth, K.; Fitzgerald, J.A.; Foust, K.D.; Kielland, T. Self-complementary AAV9 gene delivery partially corrects pathology associated with juvenile neuronal ceroid lipofuscinosis (CLN3). J. Neurosci. 2016, 36, 9669–9682. [CrossRef]

42. Hughes, S.M.; Hope, K.M.; Xu, J.B.; Mitchell, N.L.; Palmer, D.N. Inhibition of storage pathology in prenatal CLN5-deficient sheep neural cultures by lentiviral gene therapy. Neurobiol. Dis. 2014, 62, 543–550. [CrossRef]

43. Mitchell, N.L.; Russell, K.N.; Wellby, M.P.; Wicky, H.E.; Schoderboeck, L.; Barrell, G.K.; Melzer, T.R.; Gray, S.J.; Hughes, S.M.; Palmer, D.N. Longitudinal in vivo monitoring of the CNS demonstrates the efficacy of gene therapy in a sheep model of CLN5 batten disease. Mol. Ther. 2018, 26, 2366–2378. [CrossRef]

44. Kinarivala, N.; Trippier, P.C. Progress in the development of small molecule therapeutics for the treatment of neuronal ceroid lipofuscinoses (NCLs). J. Med. Chem. 2016, 59, 4415–4427. [CrossRef]

45. Rosenberg, J.B.; Chen, A.; Kaminsky, S.M.; Crystal, R.G.; Sondhi, D. Advances in the Treatment of Neuronal Ceroid Lipofuscinoses. Expert Opin. Orphan Drugs 2019, 7, 473–500. [CrossRef] [PubMed]

46. Zhang, Z.; Butler, J.D.; Levin, S.W.; Wisniewski, K.E.; Brooks, S.S.; Mukherjee, A.B. Lysosomal ceroid depletion by drugs: Therapeutic implications for a hereditary neurodegenerative disease of childhood. Nat. Med. 2001, 7, 478–484. [CrossRef]

47. Hofmann, S.L.; Lee, L.A.; Lu, J.Y.; Verkruyse, L.A. Palmitoyl-protein thioesterase and the molecular pathogenesis of infantile neuronal ceroid lipofuscinosis. Neuporphiatricats 1997, 28, 27–30. [CrossRef] [PubMed]

48. Roberts, M.S.; Macauley, S.L.; Wong, A.M.; Yilmaz, D.; Hohm, S.; Cooper, J.D.; Sands, M.S. Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis. J. Inherit. Metab. Dis. 2012, 35, 847–857. [CrossRef]

49. Gavin, M.; Wen, G.Y.; Messing, J.; Adelman, S.; Logush, A.; Jenkins, E.C.; Brown, W.T.; Velinov, M. Substrate reduction therapy in patients with milder CLN1 mutations and juvenile-onset batten disease using cysteamine bitartrate. JIMD Rep. 2013, 11, 87–92.

50. Levin, S.W.; Baker, E.H.; Zein, W.M.; Zhang, Z.; Quezado, Z.M.; Gropman, A.; Griffin, K.J.; Bianconi, S.; Chandra, G.; et al. Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: A pilot study. Lancet Neurol. 2014, 13, 777–787. [CrossRef]

51. Aldrich, A.; Bosch, M.E.; Fallet, R.; Odvody, J.; Burkovetskaya, M.; Rao, K.V.R.; Cooper, J.D.; Drack, A.V.; Kielland, T. Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3). J. Med. Chem. 2015, 8, 903–914. [CrossRef]

52. Groh, J.; Berve, K.; Martini, R. Fingolimod and teriflunomide attenuate neurodegeneration in mouse models of neuronal ceroid lipofuscinosis. Mol. Ther. 2015, 23, 1889–1899. [CrossRef] [PubMed]

53. Seehafer, S.S.; Ramirez-Montealegre, D.; Wong, A.M.; Chan, C.H.; Castaneda, J.; Horak, M.; Ahmadi, S.M.; Lim, M.J.; Cooper, J.D.; Pearce, D.A. Immunosuppression alters disease severity in juvenile Batten disease mice. J. Neuroimmunol. 2011, 230, 169–172. [CrossRef] [PubMed]

54. Augustine, E.F.; Beck, C.A.; Adams, H.R.; Defendorf, S.; Vierhile, A.; Timm, D.; Weimer, J.M.; Mink, J.W.; Marshall, F.J. Short-term administration of mycophenolate is well-tolerated in CLN3 disease (juvenile neuronal ceroid lipofuscinosis). JIMD Rep. 2019, 43, 117–124.

55. Martina, J.A.; Chen, Y.; Gucek, M.; Puertollano, R. mTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy 2018, 8, 903–914. [CrossRef]

56. Roczniak-Ferguson, A.; Petit, C.S.; Froehlich, F.; Qian, S.; Ky, J.; Angarola, B.; Walther, T.C.; Ferguson, S.M. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci. Signal. 2012, 5, ra42. [CrossRef] [PubMed]

57. Settembre, C.; Zoncu, R.; Medina, D.L.; Vetrini, F.; Erdin, S.; Erdin, S.; Huynh, T.; Ferron, M.; Karsenty, G.; Vellard, M.C.; et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 2012, 31, 1095–1108. [CrossRef] [PubMed]

58. Palmieri, M.; Pal, R.; Nelvagal, H.R.; Lotfi, P.; Stinnett, G.R.; Seymour, M.L.; Chaudhury, A.; Rajadurai, L.; Bondar, V.V.; Bremner, L.; et al. mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. Nat. Commun. 2017, 8, 14338. [CrossRef]

59. Cendret, V.; Legigan, T.; Mingot, A.; Thibaudeau, S.; Adachi, I.; Forcella, M.; Parenti, P.; Bertrand, J.; Becq, F.; Norez, C.; et al. Synthetic deoxynojirikimycin derivatives bearing a thiolated, fluorinated or unsaturated N-alkyl chain: Identification of potent alpha-glucosidase and trehalase inhibitors as well as F508del-CFTR correctors. Org. Biomol. Chem. 2015, 13, 10734–10744. [CrossRef] [PubMed]

60. Dhar, S.; Bitting, R.L.; Rylova, S.N.; Jansen, P.J.; Lockhart, E.; Koeberl, D.D.; Amalfitano, A.; Boustany, R.M. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann. Neurol. 2002, 51, 448–466. [CrossRef] [PubMed]
61. Makoukji, J.; Saadeh, F.; Mansour, K.A.; El-Sitt, S.; al Ali, J.; Kinarivala, N.; Trippier, P.C.; Boustany, R.M. Flupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses. *Ann. Clin. Transl. Neurol.* 2018, 5, 1089–1103. [CrossRef] [PubMed]

62. Kinarivala, N.; Patel, R.; Boustany, R.M.; Al-Ahmad, A.; Trippier, P.C. Discovery of aromatic carbamates that confer neuroprotective activity by enhancing autophagy and inducing the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2). *J. Med. Chem.* 2017, 60, 9739–9756. [CrossRef] [PubMed]

63. Kinarivala, N.; Morsy, A.; Patel, R.; Carmona, A.V.; Sahib, M.S.; Raut, S.; Mikelis, C.M.; Al-Ahmad, A.; Trippier, P.C. An iPSC-derived neuron model of CLN3 disease facilitates small molecule phenotypic screening. *ACS Pharmacol. Transl. Sci.* 2020, 3, 931–947. [CrossRef] [PubMed]

64. Maalouf, K.; Makoukji, J.; Saab, S.; Makhoul, N.J.; Carmona, A.V.; Kinarivala, N.; Ghanem, N.; Trippier, P.C.; Boustany, R.M. Exogenous flupirtine as potential treatment for CLN3 disease. *Cells* 2020, 9, 1872. [CrossRef] [PubMed]

65. Bond, M.; Holthaus, S.M.; Tammenn, I.; Tear, G.; Russell, C. Use of model organisms for the study of neuronal ceroid lipofuscinosis. *Biochim. Biophys. Acta* 2013, 1832, 1842–1865. [CrossRef] [PubMed]

66. Katz, M.L.; Rustad, E.; Robinson, G.O.; Whiting, R.E.H.; Student, J.T.; Coates, J.R.; Nafstrom, K. Canine neuronal ceroid lipofuscinoses: Promising models for preclinical testing of therapeutic interventions. *Neurobiol. Dis.* 2017, 108, 277–287. [CrossRef] [PubMed]

67. Jalanko, A.; Braulke, T. Neuronal ceroid lipofuscinoses. *Biochim. Biophys. Acta* 2009, 1793, 697–709. [CrossRef]

68. Palmer, D.N. The relevance of the storage of subunit c of ATP synthase in different forms and models of Batten disease (NCLs). *Biochim. Biophys. Acta* 2015, 1852, 2287–2291. [CrossRef]

69. Jalanko, A.; Vesa, J.; Manninen, T.; von Schantz, C.; Minye, H.; Fabritius, A.L.; Salonen, T.; Rapola, J.; Gentile, M.; Kopra, O.; et al. Mice with Ppt1Deltaex4 mutation replicate the INCL phenotype and show an inflammation-associated loss of interneurons. *Neurobiol. Dis.* 2005, 18, 226–241. [CrossRef] [PubMed]

70. Sondhi, D.; Hackett, N.R.; Peterson, D.A.; Stratton, J.; Baad, M.; Travis, K.M.; Wilson, J.M.; Crystal, R.G. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. *Mol. Ther.* 2007, 15, 481–491. [CrossRef] [PubMed]

71. Xu, S.; Wang, L.; El-Banna, M.; Sohar, I.; Sletat, D.E.; Lobel, P. Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis. *Mol. Ther.* 2011, 19, 1842–1848. [CrossRef]

72. Kovacs, A.D.; Pearce, D.A. Finding the most appropriate mouse model of juvenile CLN3 (Batten) disease for therapeutic studies: The importance of genetic background and gender. *Dis. Models Mech.* 2015, 8, 351–361. [CrossRef]

73. Sondhi, D.; Scott, E.C.; Chen, A.; Hackett, N.R.; Wong, A.M.; Kubiaik, A.; Nivelgall, H.R.; Pearse, Y.; Cotman, S.L.; Cooper, J.D.; et al. Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene. *Hum. Gene Ther.* 2014, 25, 223–239. [CrossRef] [PubMed]

74. Wiley, L.A.; Burnight, E.R.; Drack, A.V.; Banach, B.B.; Ochoa, D.; Cranston, C.M.; Madumba, R.A.; East, J.S.; Mullins, R.F.; Stone, E.M.; et al. Using patient-specific induced pluripotent stem cells and wild-type mice to develop a gene augmentation-based strategy to treat CLN3-associated retinal degeneration. *Hum. Gene Ther.* 2016, 27, 835–846. [CrossRef]

75. Courtine, G.; Bunge, M.B.; Fawcett, J.W.; Grossman, R.G.; Kaas, J.H.; Lemon, R.; Maier, I.; Martin, J.; et al. Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans? *Nat. Med.* 2007, 13, 561–566. [CrossRef] [PubMed]

76. van der Worp, H.B.; Howells, D.W.; Sena, E.S.; Port, L.; O’Collins, V.; Macleod, M.R. Can animal models of disease reliably inform human studies? *PLoS Med.* 2010, 7, e1000245. [CrossRef]

77. Selden, N.R.; Al-Uzri, A.; Huhn, S.L.; Koch, T.K.; Sikora, D.M.; Al-Ahmad, A.; Trippier, P.C. Discovery of aromatic carbamates that confer neuroprotective activity by enhancing autophagy and inducing the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2). *J. Med. Chem.* 2017, 60, 9739–9756. [CrossRef] [PubMed]

78. Botstein, D.; Fink, G.R. Yeast: An experimental organism for modern biology. *Science* 1988, 240, 1439–1443. [CrossRef] [PubMed]

79. McLaren, M.D.; Mathavarajah, S.; Huber, R.J. Recent insights into NCL protein function using the model organism Dictyostelium discoideum. *Cells* 2019, 8, 115. [CrossRef] [PubMed]

80. Mullins, R.F.; Stone, E.M.; et al. Using patient-specific induced pluripotent stem cells and wild-type mice to develop a gene augmentation-based strategy to treat CLN3-associated retinal degeneration. *Hum. Gene Ther.* 2016, 27, 835–846. [CrossRef] [PubMed]

81. Bennett, M.J.; Chern, L.; Carpenter, K.H.; Sladky, J.T. Abnormal lysosomal cathepsin activities in leukocytes and cultured skin fibroblasts in late infantile, but not in juvenile neuronal ceroid-lipofuscinosis (Batten disease). *Clin. Chim. Acta* 1992, 208, 111–117. [CrossRef]
86. Seehafer, S.S.; Pearce, D.A. Spectral properties and mechanisms that underlie autofluorescent accumulations in Batten disease. *Biochim. Biophys. Res. Commun.* 2009, 382, 247–251. [CrossRef]

87. Valadez-Barba, V.; Cota-Coronado, A.; Hernandez-Perez, O.R.; Lugo-Fabres, P.H.; Padilla-Camberos, E.; Diaz, N.F.; Diaz-Martinez, N.E. iPSC for modeling neurodegenerative disorders. *Regen. Ther.* 2020, 15, 332–339. [CrossRef]

88. de Rus Jacquet, A.; Denis, H.L.; Cicchetti, F.; Alpough, M. Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders. *Mol. Psychiatry* 2021, 26, 2685–2706. [CrossRef]

89. Morsy, A.; Trippier, P.C. Current and emerging pharmacological targets for the treatment of Alzheimer’s disease. *J. Alzheimers Dis.* 2019, 72, S145–S176. [CrossRef]

90. Bahmad, H.; Hadadeh, O.; Cheaito, K.; Darwish, B.; Makkawi, A.K.; Abou-Kheir, W. Modeling human neurological and neurodegenerative diseases: From induced pluripotent stem cells to neuronal differentiation and its applications in neurotrauma. *Front. Mol. Neurosci.* 2017, 10, 50. [CrossRef]

91. Bellin, M.; Marchetto, M.C.; Gage, F.H.; Mummery, C.L. Induced pluripotent stem cells: The new patient? *Nat. Rev. Mol. Cell. Biol.* 2012, 13, 713–726. [CrossRef]

92. Shi, Y.; Ionue, H.; Wu, J.C.; Yamanaka, S. Induced pluripotent stem cell technology: A decade of progress. *Nat. Rev. Drug Discov.* 2017, 16, 115–130. [CrossRef]

93. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007, 131, 861–872. [CrossRef]

94. Lancaster, M.A.; Renner, M.; Martin, C.A.; Wenzel, D.; Bicknell, D.S.; Hurles, M.E.; Homfray, T.; Penninger, J.M.; Jackson, A.P.; Knoblich, J.A. Cerebral organoids model human brain development and microcephaly. *Nature* 2013, 501, 373–379. [CrossRef]

95. Hoing, S.; Rudhard, Y.; Reinhardt, P.; Glatz, M.; Stelhing, M.; Wu, G.; Peiker, C.; Bocker, A.; Parga, J.A.; Bunk, E.; et al. Discovery of inhibitors of microglial neurotoxicity acting through multiple mechanisms using a stem-cell-based phenotypic assay. *Cell Stem Cell* 2012, 11, 620–632. [CrossRef]

96. Li, M.; Zhao, H.; Ananiev, G.E.; Musser, M.T.; Ness, K.H.; Maglaque, D.L.; Saha, K.; Bhattacharyya, A.; Zhao, X. Establishment of Reporter Lines for Detecting Fragile X Mental Retardation (FMR1) Gene Reactivation in Human Neural Cells. *Stem Cells* 2017, 35, 158–169. [CrossRef]

97. Kawatou, M.; Masumoto, H.; Fukushima, H.; Morinaga, G.; Sakata, R.; Ashihara, T.; Yamashita, J.K. Modelling Torsade de Pointes arrhythmias in vitro in 3D human iPS cell-engineered heart tissue. *Nat. Commun.* 2017, 8, 1078. [CrossRef] [PubMed]

98. Spence, J.R.; Mayhew, C.N.; Rankin, S.A.; Kuhar, M.F.; Vallance, J.E.; Tolle, K.; Hoskins, E.E.; Kalinichenko, V.V.; Wells, S.I.; Zorn, A.M.; et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. *Nature* 2011, 470, 105–109. [CrossRef]

99. Hockemeyer, D.; Jaenisch, R. Induced Pluripotent Stem Cells Meet Genome Editing. *Cell Stem Cell* 2016, 18, 573–586. [CrossRef] [PubMed]

100. Hotta, A.; Yamanaka, S. From genomics to gene therapy: Induced pluripotent stem cells meet genome editing. *Annu. Rev. Genet.* 2015, 49, 47–70. [CrossRef] [PubMed]

101. Zhang, X.; Zhang, D.; Chen, S.C.; Lamey, T.; Thompson, J.A.; McLaren, T.; de Roach, J.N.; Chen, F.K.; McLenachan, S. Generation of an induced pluripotent stem cell line from a patient with non-syndromic CLN3-associated retinal degeneration and a coisogenic control line. *Stem Cell Res.* 2018, 29, 245–249. [CrossRef]

102. Burnight, E.R.; Bohrer, L.R.; Giacalone, J.C.; Klaahsen, D.L.; Daggett, H.T.; East, J.S.; Madumba, R.A.; Worthington, K.S.; Mullins, R.F.; Stone, E.M.; et al. CRISPR-Cas9-mediated correction of the 1.02 kb common deletion in CLN3 in induced pluripotent stem cells from patients with batten disease. *CRISPR J.* 2018, 1, 75–87. [CrossRef]

103. Gomez-Giro, G.; Arias-Fuenzalida, J.; Jarazo, J.; Zeuschner, D.; Ali, M.; Possemis, N.; Bolognin, S.; Balder, R.; Jager, C.; Kuper, W.F.E.; et al. Synapase alterations precede neuronal damage and storage pathology in a human cerebral organoid model of CLN3 juvenile neuronal ceroid lipofuscinosis. *Acta. Neuropathol. Commun.* 2019, 7, 222. [CrossRef]

104. Keller, J.N.; Huang, F.F.; Markesbery, W.R. Decreased levels of proteasome activity and proteasome expression in aging spinal cord. *Neuroscience* 2000, 98, 149–156. [CrossRef]

105. Sima, N.; Li, R.; Huang, W.; Xu, M.; Beers, J.; Zou, J.; Titus, E.A.; Marugan, J.J.; Xie, J.; et al. Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses. *Orphanet J. Rare Dis.* 2018, 13, 54. [CrossRef] [PubMed]

106. Lojewski, X.; Staropoli, J.F.; Biswas-Legrand, S.; Simas, A.M.; Halivi, L.; Selig, M.K.; Coppell, S.H.; Goss, K.A.; Petcherski, A.; Chandrachud, U.; et al. Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway. *Hum. Mol. Genet.* 2014, 23, 2005–2022. [CrossRef]

107. Tang, C.; Han, J.; Dalvi, S.; Manian, K.; Wünschel, L.; Volland, S.; Soto, C.A.; Galloway, C.A.; Spencer, W.; Roll, M.; et al. A human model of batten disease shows role of CLN3 in phagocytosis at the photoreceptor-RPE interface. *Commun. Biol.* 2021, 4, 161. [CrossRef] [PubMed]

108. Uusi-Rauva, K.; Blom, T.; von Schantz-Fant, C.; Blom, T.; Jalanko, A.; Kyttilä, A. Induced pluripotent stem cells derived from a CLN5 patient manifest phenotypic characteristics of neuronal ceroid lipofuscinoses. *Int. J. Mol. Sci.* 2017, 18, 955. [CrossRef] [PubMed]
109. Chandrachud, U.; Walker, M.W.; Simas, A.M.; Heetveld, S.; Petcherski, A.; Klein, M.; Oh, H.; Wolf, P.; Zhao, W.N.; Norton, S.; et al. Unbiased Cell-based Screening in a Neuronal Cell Model of Batten Disease Highlights an Interaction between $\text{Ca}^{2+}$ Homeostasis, Autophagy, and CLN3 Protein Function. *J. Biol. Chem.* 2015, 290, 14361–14380. [CrossRef]

110. Grubman, A.; Pollari, E.; Duncan, C.; Caragounis, A.; Blom, T.; Volitakis, I.; Wong, A.; Cooper, J.; Crouch, P.J.; Koistinaho, J.; et al. Deregulation of biometal homeostasis: The missing link for neuronal ceroid lipofuscinoses? *Metallomics* 2014, 6, 932–943. [CrossRef]

111. Wavre-Shapton, S.T.; Calvi, A.A.; Turmaine, M.; Seabra, M.C.; Cutler, D.F.; Futter, C.E.; Mitchison, H.M. Photoreceptor phagosome processing defects and disturbed autophagy in retinal pigment epithelium of Cln3$\text{ex}^{−6}$ mice modelling juvenile neuronal ceroid lipofuscinoses (Batten disease). *Hum. Mol. Genet.* 2015, 24, 7060–7074. [PubMed]